Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G, Williamson S, Pajarillo R, Paruzzo L, Chen L, Grady C, Doucette A, Nemecek E, Gabrielli G, Barta SK, Svoboda J, Chong EA, Yelton R, Nasta SD, Landsburg DJ, Ugwuanyi O, Chen AI, Schachter L, White G, Ballard HJ, Weber E, Curley C, Porter DL, Garfall AL, Hwang WT, Guerra CE, Maziarz RT, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: ruella m. NEJM Evid. 2024 Apr;3(4):EVIDoa2300213. doi: 10.1056/EVIDoa2300213. Epub 2024 Mar 26. NEJM Evid. 2024. PMID: 38776868
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome.
Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. Vinnakota JM, et al. Among authors: ruella m. Nat Cancer. 2024 May 13. doi: 10.1038/s43018-024-00764-7. Online ahead of print. Nat Cancer. 2024. PMID: 38741011
CAR T cell resistance to oncogenic transformation.
Ruella M, June CH. Ruella M, et al. Blood Cancer Discov. 2024 May 7. doi: 10.1158/2643-3230.BCD-23-0273. Online ahead of print. Blood Cancer Discov. 2024. PMID: 38713827
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells.
Ma L, Ramasubramanian R, Mehta N, Cossette B, Morgan D, Sukaj I, Bergaggio E, Kadauke S, Myers R, Paruzzo L, Ghilardi G, Grzywa T, Cozzone A, Schuster S, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp S, Chiarle R, Wittrup KD, Irvine DJ. Ma L, et al. Among authors: ruella m. bioRxiv [Preprint]. 2024 Apr 30:2024.04.16.589780. doi: 10.1101/2024.04.16.589780. bioRxiv. 2024. PMID: 38659938 Free PMC article. Preprint.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, Chong EA, Gabrielli G, Nasta SD, Landsburg DJ, Carter J, Pajarillo R, Barta SK, White G, Weber E, Napier E, Porter DL, Garfall AL, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: ruella m. J Hematol Oncol. 2024 Apr 22;17(1):19. doi: 10.1186/s13045-024-01542-9. J Hematol Oncol. 2024. PMID: 38644469 Free PMC article.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA, Chong ER, Therwhanger D, Nasta SD, Landsburg DJ, Barta SK, Svoboda J, Gerson JN, Ghilardi G, Paruzzo L, Fraietta JA, Weber E, Stefano N, Porter DL, Frey NV, Garfall AL, Ruella M, Schuster SJ. Chong EA, et al. Among authors: ruella m. Transplant Cell Ther. 2024 Mar 16:S2666-6367(24)00288-4. doi: 10.1016/j.jtct.2024.03.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38494076
Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
Chong EA, Kumashie KG, Chong ER, Fabrizio J, Gupta A, Svoboda J, Barta SK, Walsh KM, Napier EB, Lundberg RK, Nasta SD, Gerson JN, Landsburg DJ, Gonzalez J, Gaano A, Weirick ME, McAllister CM, Awofolaju M, John GN, Kammerman SC, Novaceck J, Pajarillo R, Lundgreen KA, Tanenbaum N, Gouma S, Drapeau EM, Adamski S, D'Andrea K, Pattekar A, Hicks A, Korte S, Sharma H, Herring S, Williams JC, Hamilton JT, Bates P, Hensley SE, Prak ETL, Greenplate AR, Wherry EJ, Schuster SJ, Ruella M, Vella LA. Chong EA, et al. Among authors: ruella m. J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093/infdis/jiae106. Online ahead of print. J Infect Dis. 2024. PMID: 38437622
119 results